News & Updates

Luspatercept bests epoetin alfa in head-to-head LR–MDS-related anaemia trial

17 Jul 2023 by

In the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (LR-MDS), luspatercept seems to perform better than epoetin alfa at restoring iron stores, according to the interim results of the open-label phase III COMMANDS trial.

Luspatercept bests epoetin alfa in head-to-head LR–MDS-related anaemia trial

17 Jul 2023

Does the type of facility affect outcomes in patients with Merkel cell carcinoma?

17 Jul 2023

Treatment of Merkel cell carcinoma (MCC), a rare neuroendocrine skin cancer with high mortality and rising incidence, at either an academic or a high-volume centre tends to lead to better patient survival, as shown in a recent study.

Does the type of facility affect outcomes in patients with Merkel cell carcinoma?

17 Jul 2023

Neutrophils may pave the way for new-generation immunotherapy

17 Jul 2023 by

Neutrophils play a crucial role in suppressing or promoting tumour growth. Gene-edited neutrophils with SMAD3 deletion enhance neutrophil-mediated antitumour activity in non-small-cell lung cancer (NSCLC), according to researchers from the Chinese University of Hong Kong (CUHK).

Neutrophils may pave the way for new-generation immunotherapy

17 Jul 2023

QUIWI: FLT3 type II inhibitor confers survival advantage in acute myeloid leukaemia

13 Jul 2023 by

The FLT3 type II inhibitor quizartinib, when combined with induction and consolidated therapy and continued for up to 12 cycles, yields survival benefits such as prolonged overall and relapse-free survival in patients with newly diagnosed wild-type acute myeloid leukaemia (AML), as shown in the interim results of the phase II study QUIWI.

QUIWI: FLT3 type II inhibitor confers survival advantage in acute myeloid leukaemia

13 Jul 2023

Mirvetuximab soravtansine improves survival in platinum-resistant ovarian cancer

13 Jul 2023 by

Treatment with mirvetuximab soravtansine, an antibody-drug conjugate (ADC) targeting folate receptor-alpha (FRα), led to significantly better survival outcomes in women with platinum-resistant ovarian cancer (PROC) compared with the investigator’s choice of chemotherapy, according to the MIRASOL trial presented at ASCO 2023.

Mirvetuximab soravtansine improves survival in platinum-resistant ovarian cancer

13 Jul 2023

Prediction model for stage I NSCLC refines follow-up strategy, personalizes therapy

12 Jul 2023

A prediction model on disease recurrence for low-risk, resected stage I lung adenocarcinoma can classify postoperative patients with available clinical information and may even aid in personalizing a follow-up strategy and future adjuvant therapy, reports a study.

Prediction model for stage I NSCLC refines follow-up strategy, personalizes therapy

12 Jul 2023

S-ketamine anaesthesia improves recovery following modified radical mastectomy

12 Jul 2023 by

A prospective randomized controlled trial of breast cancer (BC) patients undergoing modified radical mastectomy (MRM) finds that S-ketamine used in place of sufentanil for general anaesthesia (GA) improves postoperative recovery.

S-ketamine anaesthesia improves recovery following modified radical mastectomy

12 Jul 2023

Palliative care for interstitial lung disease more difficult than for lung cancer

11 Jul 2023

Providing palliative care (PC) for patients with interstitial lung disease (ILD) appears more challenging than for those with lung cancer (LC), according to a study. Pulmonary specialists have also cited some ILD-specific barriers in PC.

Palliative care for interstitial lung disease more difficult than for lung cancer

11 Jul 2023

KEYNOTE-826: Sustained survival benefit with pembro + chemo in advanced cervical cancer

11 Jul 2023 by

The addition of pembrolizumab immunotherapy to chemotherapy, either with or without bevacizumab, continues to confer survival benefit in patients with persistent, recurrent, or metastatic cervical cancer, regardless of their programmed death-ligand 1 (PD-L1) combined positive score (CPS), according to the updated results of the KEYNOTE-826 trial presented at ASCO 2023.

KEYNOTE-826: Sustained survival benefit with pembro + chemo in advanced cervical cancer

11 Jul 2023

Does polypharmacy affect survival in older patients with haematological malignancy?

10 Jul 2023 by

Polypharmacy does not appear to result in poorer treatment response and survival in older patients with different haematological malignancies, as shown in a study presented at the recent EHA 2023.

Does polypharmacy affect survival in older patients with haematological malignancy?

10 Jul 2023

News & Updates

Filter by Specialty:

Specialty:

Luspatercept bests epoetin alfa in head-to-head LR–MDS-related anaemia trial

Luspatercept bests epoetin alfa in head-to-head LR–MDS-related anaemia trial

Does the type of facility affect outcomes in patients with Merkel cell carcinoma?

Does the type of facility affect outcomes in patients with Merkel cell carcinoma?

Neutrophils may pave the way for new-generation immunotherapy

Neutrophils may pave the way for new-generation immunotherapy

QUIWI: FLT3 type II inhibitor confers survival advantage in acute myeloid leukaemia

QUIWI: FLT3 type II inhibitor confers survival advantage in acute myeloid leukaemia

Mirvetuximab soravtansine improves survival in platinum-resistant ovarian cancer

Mirvetuximab soravtansine improves survival in platinum-resistant ovarian cancer

Prediction model for stage I NSCLC refines follow-up strategy, personalizes therapy

Prediction model for stage I NSCLC refines follow-up strategy, personalizes therapy

S-ketamine anaesthesia improves recovery following modified radical mastectomy

S-ketamine anaesthesia improves recovery following modified radical mastectomy

Palliative care for interstitial lung disease more difficult than for lung cancer

Palliative care for interstitial lung disease more difficult than for lung cancer

KEYNOTE-826: Sustained survival benefit with pembro + chemo in advanced cervical cancer

KEYNOTE-826: Sustained survival benefit with pembro + chemo in advanced cervical cancer

Does polypharmacy affect survival in older patients with haematological malignancy?

Does polypharmacy affect survival in older patients with haematological malignancy?